International Clinical Psychopharmacology最新文献_第9页

Mental health in patients affected by atopic dermatitis: which effects of treatment with dupilumab? 特应性皮炎患者的心理健康：杜匹单抗治疗有哪些效果？

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-12-22 DOI: 10.1097/YIC.0000000000000511

Silvia Mariel Ferrucci, Simona Tavecchio, Gregorio Nicolini, Luisa Angileri, Alessandro Ceresa, Giulia Del Tordello, Emilio Berti, Angelo Valerio Marzano, Massimiliano Buoli

{"title":"Mental health in patients affected by atopic dermatitis: which effects of treatment with dupilumab?","authors":"Silvia Mariel Ferrucci, Simona Tavecchio, Gregorio Nicolini, Luisa Angileri, Alessandro Ceresa, Giulia Del Tordello, Emilio Berti, Angelo Valerio Marzano, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000511","DOIUrl":"10.1097/YIC.0000000000000511","url":null,"abstract":"Atopic dermatitis (AD) is an inflammatory skin disease. Patients with AD are prone to develop anxiety and mood disorders. Aim of this study is to investigate if treatment with dupilumab may improve mental health status of patients affected by AD. A total of 66 patients with severe AD were included: 24 subjects were candidate or have just started (one month) treatment with dupilumab, and 42 have been in treatment for one year. 25.8%, 30.3%, and 45.5% of the total sample showed, respectively, clinically significant anxiety, depression, and symptoms of Internet addiction. Patients with anxiety symptoms resulted to have more severe AD, more sleep problems ( P = 0.028), less quality of life ( P = 0.001), more severe depressive symptoms ( P < 0.001), to be more frequently women ( P = 0.016), to be less frequently treated with dupilumab for one year ( P = 0.025). Similarly, patients with clinically significant depressive symptoms resulted to have more severe AD, more sleep problems ( P = 0.003), less quality of life ( P < 0.001), more severe anxiety symptoms ( P < 0.001), to be less frequently treated with dupilumab for one year ( P = 0.008). Patients with AD treated for one year with dupilumab showed a better mental health profile in terms of less severe anxiety and depression with respect to their counterparts.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"201-205"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41178724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive overview of post-stroke depression treatment options. 全面概述中风后抑郁治疗方案。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-12-27 DOI: 10.1097/YIC.0000000000000532

Alberto Raggi, Alessandro Serretti, Raffaele Ferri

引用次数: 0

Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics. 使用氯氮平与其他抗精神病药物的患者感染 COVID-19 后中性粒细胞绝对计数的变化。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1097/YIC.0000000000000506

Seong Hoon Jeong, Mi Gyung Lee, Yong Sik Kim, In Won Chung

{"title":"Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics.","authors":"Seong Hoon Jeong, Mi Gyung Lee, Yong Sik Kim, In Won Chung","doi":"10.1097/YIC.0000000000000506","DOIUrl":"10.1097/YIC.0000000000000506","url":null,"abstract":"It was reported that patients who contracted COVID-19 while taking clozapine exhibited a distinct hematological response. However, the absence of control groups made it difficult to attribute it to clozapine. The changes in absolute neutrophil counts (ANCs) during the 4 weeks after COVID-19 infection were compared between the two groups of patients with severe mental illnesses (SMIs) (49 patients using clozapine and 54 using other antipsychotics) using generalized additive modeling. Although the pattern of a transient drop in ANC followed by gradual recovery could be demonstrated in both groups, it was more pronounced in the clozapine group ( P = 0.00025). Nevertheless, overall ANC remained at a higher level in the clozapine group. The results suggested potential interaction between clozapine and COVID-19 at the level of hematological dynamics. However, it did not necessarily indicate that such interaction is inevitably harmful or dangerous. It was more of a concern that some patients using other antipsychotics exhibited decreased ANC, which did not easily recover. Traditionally, clinicians have been concerned about the worsening of hematological side effects in clozapine patients after COVID-19 infection. However, the obtained result highlighted the necessity of hematological monitoring in patients using any type of antipsychotics for SMIs.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"187-194"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial. 舍曲林和西酞普兰对重度抑郁症疗效的性别差异：随机双盲试验。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-04-18 DOI: 10.1097/yic.0000000000000550

Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzadeh

{"title":"Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial.","authors":"Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzadeh","doi":"10.1097/yic.0000000000000550","DOIUrl":"https://doi.org/10.1097/yic.0000000000000550","url":null,"abstract":"To investigate the response to antidepressants while controlling for sex, which has been controversial, 92 outpatient males and females with major depressive disorder were assigned to sertraline (100 mg/day) or citalopram (40 mg/day) in two strata and were assessed using Hamilton depression rating scale (HDRS) scores and brain-derived neurotrophic factor (BDNF), interleukin (IL)-6 and cortisol serum levels in this 8-week, randomized, parallel-group, double-blind clinical trial. Data of 40 sertraline and 40 citalopram recipients with equal representation of males and females assigned to each medication were analyzed, while their baseline characteristics were not statistically different (P > 0.05). There were no significant differences between sertraline and citalopram recipients in outcome changes (P > 0.05), all of which indicated improvement, but a significant time-treatment-sex interaction effect in BDNF levels was observed (P = 0.035). Regarding this, subgroup analyses illustrated a significantly greater increase in male BDNF levels following sertraline treatment (P = 0.020) with a moderate to large effect size (Cohen's d = 0.76 and ). Significant associations were observed between percentage changes in IL-6 levels and BDNF levels in sertraline recipients (P = 0.033) and HDRS scores in citalopram recipients (P < 0.001). Sex was an effect modifier in BDNF alterations following sertraline and citalopram administration. Further large-scale, high-quality, long-term studies are recommended.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"50 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential effects of sertraline and cognitive behavioural therapy on behavioural inhibition in patients with obsessive compulsive disorder. 舍曲林和认知行为疗法对强迫症患者行为抑制的不同影响。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-04-02 DOI: 10.1097/yic.0000000000000548

Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg

{"title":"Differential effects of sertraline and cognitive behavioural therapy on behavioural inhibition in patients with obsessive compulsive disorder.","authors":"Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg","doi":"10.1097/yic.0000000000000548","DOIUrl":"https://doi.org/10.1097/yic.0000000000000548","url":null,"abstract":"Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at week 16. The stop signal reaction time task (SSRT) was used to evaluate motor impulsivity and attentional flexibility was evaluated using the intra/extra-dimensional set shifting task. Paired-samples t-tests or nonparametric variants were used to compare baseline and posttreatment scores within each treatment group. Forty-five patients were tested at baseline (sertraline n = 14; CBT n = 14; sertraline + CBT n = 17) and 23 patients at week 16 (sertraline n = 6; CBT n = 7; sertraline + CBT n = 10). The mean dosage of sertraline was numerically higher in those taking sertraline as a monotherapy (166.67 mg) compared with those taking sertraline in combination with CBT (100 mg). Analysis of pre-post treatment scores using an intent-to-treat-analysis found a significant reduction in the SSRT in those treated with sertraline, whilst there was no significant change on this task for those treated with CBT or the combination. This study found that motor inhibition improved significantly following sertraline monotherapy. Suboptimal sertraline dosing might explain the failure to detect an effect on motor inhibition in the group receiving combination of sertraline + CBT. Higher dose sertraline may have broader cognitive effects than CBT for OCD, motor impulsivity may have value as a measure of treatment outcome and, by extension, the SSRT could serve as a biomarker for personalising care.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"87 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Catatonic postpartum paternal depression as a first debut of a bipolar disorder: a case report. 作为双相情感障碍首次出现的产后紧张性父亲抑郁症：一例报告。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000480

Oscar de Juan, Albert Mas, Anna Giménez-Palomo, Joaquín Gil-Badenes, Lídia Ilzarbe, Lluc Colomer, Helena Andreu, Laura Bueno, Luis Olivier, Beatriz Estévez, Tábatha Fernández-Plaza, Laia Tardón-Senabre, Néstor Arbelo, Marc Valentí, Susana Gomes da Costa, Gabriel Pujol-Fontrodona, Eduard Vieta, Isabella Pacchiarotti

{"title":"Catatonic postpartum paternal depression as a first debut of a bipolar disorder: a case report.","authors":"Oscar de Juan, Albert Mas, Anna Giménez-Palomo, Joaquín Gil-Badenes, Lídia Ilzarbe, Lluc Colomer, Helena Andreu, Laura Bueno, Luis Olivier, Beatriz Estévez, Tábatha Fernández-Plaza, Laia Tardón-Senabre, Néstor Arbelo, Marc Valentí, Susana Gomes da Costa, Gabriel Pujol-Fontrodona, Eduard Vieta, Isabella Pacchiarotti","doi":"10.1097/YIC.0000000000000480","DOIUrl":"10.1097/YIC.0000000000000480","url":null,"abstract":"Paternal postpartum depression (PD) is considered an affective disorder that affects fathers during the months following childbirth. Interestingly, it has been observed that during these months the chances of a male parent suffering from depression are double that for a non-parent male counterpart. We present the case of a 34-year-old man with no relevant medical history in who, overlapping her daughter's birth, several depressive symptoms emerged, such as fatigue, lack of concentration, sleeping disturbances and abandonment of care of the newborn. Prior to consultation, patient refused to eat and open his eyes, and his speech became progressively more parsimonious until reaching mutism. The patient was diagnosed with a severe depressive disorder with catatonia. Given the lack of improvement with pharmacological treatment and due to the evidence of electroconvulsive therapy (ECT)'s effectiveness on patients with catatonia, acute ECT treatment was indicated and started. It should be noted that PD is an important entity to consider in our differential diagnosis of young parents who present a depressive episode. Few cases of relatively young patients presenting with such clinical presentation have been described and, although this case presents some of the characteristics described in the epidemiology of PD, other clinical aspects are not typical of this entity. Informed consent was obtained from the patient for the purpose of publication.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"113-116"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between mobile phone addiction and depression, anxiety, and sleep quality in medical students. 手机成瘾与医学生抑郁、焦虑和睡眠质量的关系。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2023-10-02 DOI: 10.1097/YIC.0000000000000517

Mahsa Nahidi, Motahareh Ahmadi, Mohammad Reza Fayyazi Bordbar, Negar Morovatdar, Majid Khadem-Rezayian, Adeleh Abdolalizadeh

{"title":"The relationship between mobile phone addiction and depression, anxiety, and sleep quality in medical students.","authors":"Mahsa Nahidi, Motahareh Ahmadi, Mohammad Reza Fayyazi Bordbar, Negar Morovatdar, Majid Khadem-Rezayian, Adeleh Abdolalizadeh","doi":"10.1097/YIC.0000000000000517","DOIUrl":"10.1097/YIC.0000000000000517","url":null,"abstract":"This study investigates the prevalence of mobile phone addiction among medical students and its relationship with depression, anxiety, and sleep quality. The study was conducted at Mashhad University of Medical Sciences from 2019 to 2021, and it included medical students at four different levels of training. Participants were selected using a stratified random sampling method. All subjects completed the Mobile Phone Addiction Scale, Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory, and Beck Anxiety Inventory through online electronic self-report questionnaires. Overall, 355 medical students were included in the study, with 203 (57.2%) being female. Mild and severe mobile phone addiction was reported by 83.7 and 2.5% of the students, respectively. Furthermore, the study's findings revealed significantly higher sleep quality disorder, depression, and anxiety scores among students with severe mobile phone addiction compared to other participants ( P < 0.001, P = 0.007, and P < 0.001, respectively). Although mobile phone addiction was prevalent, severe addiction was rare among medical students. Nevertheless, severe addiction was associated with an increased prevalence of mental health problems and sleep disturbances, emphasizing the importance of interventions aimed at reducing mobile phone addiction and improving mental health.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"70-81"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41128881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temperament and character dimensions explain self-reported resilience deficits in patients with affective disorders. 气质和性格维度可解释情感障碍患者自我报告的复原力缺陷。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2023-06-12 DOI: 10.1097/YIC.0000000000000483

Evdoxia Tsigkaropoulou, Ioannis Michopoulos, Evgenia Porichi, Konstantinos Dafnas, Alessandro Serretti, Panagiotis Ferentinos

{"title":"Temperament and character dimensions explain self-reported resilience deficits in patients with affective disorders.","authors":"Evdoxia Tsigkaropoulou, Ioannis Michopoulos, Evgenia Porichi, Konstantinos Dafnas, Alessandro Serretti, Panagiotis Ferentinos","doi":"10.1097/YIC.0000000000000483","DOIUrl":"10.1097/YIC.0000000000000483","url":null,"abstract":"This is the first study exploring how temperament and character personality dimensions impact self-reported resilience in major depressive disorder (MDD) and bipolar disorder (BD). We included 130 euthymic patients with affective disorders (AFD; 66 MDD and 64 BD) and 134 healthy controls (HC). Connor and Davidson resilience scale and Temperament and Character Inventory (TCI-140) were administered. Multiple linear regressions and interaction analyses were performed. Mediation analyses examined if personality dimensions explained group differences in resilience. Resilience was lower in MDD and BD vs. HC and in MDD vs. BD, adjusting for sex, age and education. Higher resilience was predicted by lower harm avoidance (HA) and higher persistence (P) in AFD and MDD, lower HA in BD and higher P and self-directedness (SD) in HC. However, only HA and P had a group-specific effect on resilience in AFD vs. HC. In mediation analyses, specific TCI dimensions at least partially explained differences in resilience: HA, P and SD in AFD or MDD vs. HC; SD in BD vs. HC; P in BD vs. MDD. Concludingly, two temperament traits (HA, P) and a character trait (SD) predict resilience in AFD. Focusing on personality could identify sources of compromised resilience as potential treatment targets.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"59-69"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9730965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis. 卡哌嗪对双相抑郁症且基线焦虑水平较高或较低患者的疗效：汇总后特别分析。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000500

Rakesh Jain, Roger S McIntyre, Andrew J Cutler, Willie R Earley, Huy-Binh Nguyen, Julie L Adams, Lakshmi N Yatham

{"title":"Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis.","authors":"Rakesh Jain, Roger S McIntyre, Andrew J Cutler, Willie R Earley, Huy-Binh Nguyen, Julie L Adams, Lakshmi N Yatham","doi":"10.1097/YIC.0000000000000500","DOIUrl":"10.1097/YIC.0000000000000500","url":null,"abstract":"Post hoc analyses evaluated cariprazine, a dopamine D 3 -preferring D 3 /D 2 receptor partial agonist, in patients with bipolar I depression and high baseline anxiety. Data were pooled from two phase 3, randomized, double-blind, placebo-controlled studies in adults with bipolar I disorder and a major depressive episode (NCT02670538, NCT02670551). Cariprazine 1.5 and 3 mg/d were evaluated in patient subgroups with higher and lower baseline anxiety. In patients with higher baseline anxiety, significant differences for cariprazine 1.5 mg/d versus placebo were observed on change in Montgomery-Åsberg Rating Scale (MADRS) total score, Hamilton Anxiety Rating Scale (HAM-A) total score and subscale scores, and rates of MADRS remission ( P < 0.05 all); nonsignificant numerical improvements were observed for cariprazine 3 mg/d versus placebo. In patients with lower anxiety, differences versus placebo were significant for HAM-A (cariprazine 3 mg/d) and MADRS (cariprazine 1.5 and 3 mg/d) total score changes ( P < 0.05 all). Rates of treatment-emergent mania were low and similar for cariprazine and placebo. Cariprazine 1.5 mg/d had consistent effects on anxiety and depression symptoms in patients with bipolar I depression and higher baseline anxiety; tolerability was favorable. Given few proven treatments for this common comorbidity, these preliminary results are promising.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"82-92"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10833186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential effectiveness between Ketamine and Esketamine: the predictive role of dissociative features. A treatment-resistant depression case. 氯胺酮和 Esketamine 的不同疗效：解离特征的预测作用。一个难治性抑郁症病例。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2023-07-07 DOI: 10.1097/YIC.0000000000000497

Nicola Ragone, Barbara Barbini, Carolina Passani, Federico Seghi, Cristina Colombo

引用次数: 0